Aprea Therapeutics, Inc. Insider Trading
APRE
Insiders bought 61K on the open market and sold nothing.
Get an email when APRE's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Jan 30 | Oren Gilad President/CEO | Bought | 28,100 | $0.89 | 25K | 8.1% | Form 4 |
| Jan 30 | John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Bought | 5,700 | $0.89 | 5K | 21% | Form 4 |
| Dec 10, 2025 | Marc Duey Director | Bought | 21,459 | $1.17 | 25K | 9.1% | Form 4 |
| Dec 10, 2025 | John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Bought | 5,000 | $1.17 | 6K | 22% | Form 4 |
| Apr 3, 2025 | Oren Gilad President/CEO | Bought 2 parts | 5,500 | $1.84 average | 10K | 1.6% | Form 4 |
- Jan 30Oren GiladPresident/CEO · bought 28,100 at $0.8925K8.1% of stake
- Jan 30John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr · bought 5,700 at $0.895K21% of stake
- Dec 10, 2025Marc DueyDirector · bought 21,459 at $1.1725K9.1% of stake
- Dec 10, 2025John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr · bought 5,000 at $1.176K22% of stake
- Apr 3, 2025Oren GiladPresident/CEO · bought 5,500 at avg $1.8410K1.6% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with APRE
Spot a number that looks wrong? Check it in APRE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing APRE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.